UNILIFE CORPORATION (NASDAQ:UNIS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 21, 2017, Michael Ratigan, Senior Vice President and Chief Commercial Officer of Unilife Corporation (the “Company”), notified the Company of his resignation from the Company, effective April 4, 2017. Mr. Ratigan informed the Company that he will be leaving to assume a position at a privately-held, global life sciences company.
About UNILIFE CORPORATION (NASDAQ:UNIS)
Unilife Corporation is engaged in the designing, development and manufacturing of injectable drug delivery systems. The Company has a portfolio of product platforms, including pre-filled syringes, disposable and reusable auto-injectors, drug reconstitution delivery systems, ocular delivery systems, and other systems for the targeted delivery of injectable therapies. The majority of its products are designed for sale directly to pharmaceutical and biotechnology companies supplying them as drug-device combination products, pre-filled and ready for administration by end-users, such as health-care providers or patients. Its other products, such as reusable auto-injectors and certain systems for targeted drug delivery are designed either to be sold to pharmaceutical or biotechnology companies for use as combination products or to be sold directly to a health care provider or end user without having the device pre-filled by a pharmaceutical company. UNILIFE CORPORATION (NASDAQ:UNIS) Recent Trading Information
UNILIFE CORPORATION (NASDAQ:UNIS) closed its last trading session down -0.02 at 1.80 with 49,672 shares trading hands.
